Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations


share with twitter share with LinkedIn share with facebook
09/04/2020 | 11:14am EDT

ABBOTT PARK - Abbott (NYSE: ABT) today announced the start of the LIFE-BTK clinical trial to evaluate the safety and effectiveness of the company's new Esprit BTK Everolimus Eluting Resorbable Scaffold System.

This is the first Investigational Device Exemption (IDE) trial in the U.S. to evaluate a fully resorbable device to treat blocked arteries below the knees, or critical limb ischemia (CLI), in people battling advanced stages of peripheral artery disease (PAD). The first patient was enrolled by Danielle Bajakian, M.D., a vascular surgeon at New York-Presbyterian/Columbia University Irving Medical Center.

'Far too many people are impacted by peripheral artery disease, and this new drug-eluting resorbable scaffold is needed to offer meaningful improvements in how this disease is treated,' said Nick West, M.D., divisional vice president, Medical Affairs, and chief medical officer in Abbott's vascular business. 'Patients treated with balloon angioplasty often require repeat procedures on treated arteries, and therefore a drug-eluting resorbable device is ideally-suited to provide mechanical support for the vessel, reduce the chance of vessel re-narrowing and then gradually disappear over time.'

For people with CLI, blocked vessels impair blood flow to the lower extremities, which can lead to severe pain, wounds, and in some cases, limb amputation. Globally, more than 200 million1 people suffer from PAD, disproportionally affecting people in underserved communities. Worse, up to 40% of patients with CLI currently undergo amputations,2 many of which could be prevented by eliminating health care disparities.

Currently, the standard of care for patients battling CLI is balloon angioplasty, which relies on a small balloon delivered via a catheter to the blockage to compress it against the arterial wall, opening the vessel and restoring blood flow. However, blockages treated only with balloon angioplasty have poor short- and long-term results, and in many instances the vessels become blocked again, requiring additional treatment.

There are no drug-eluting stents (DES), drug-coated balloons (DCB) or bare-metal stents (BMS) approved for use below the knee (BTK) in the U.S. With the limited options for BTK, new treatment options are needed. The U.S. Food and Drug Administration (FDA) has granted Esprit BTK breakthrough device designation, which streamlines review and pre-market approval timelines.

Unlike traditional metal stents, Abbott's Esprit BTK System is not a permanent implant; it provides support to an artery immediately after a balloon angioplasty, preventing the vessel from reclosing. Once implanted, the scaffold delivers a drug over a few months that promotes healing and keeps the artery open. The scaffold is naturally resorbed into the body over time, like dissolving sutures, and ultimately leaves only a healed artery behind. Abbott is a pioneer in bioresorbable scaffolds. Long-term clinical data from a meta-analysis of randomized Absorb trials suggested that bioresorbable scaffolds might be an acceptable alternative to metallic DES for many patients with coronary artery disease.3

'After a five-year feasibility study in assessing treatment of arteries below the knee with a different version of this technology, the outcomes suggest resorbable devices have significant potential to become the favored therapy for CLI patients,' said Ramon Varcoe, MBBS MS FRACS Ph.D., University New South Wales, Sydney, Australia, and one of the principal investigators in the trial. 'This technology offers the best of both worlds. The device provides a strong scaffold structure and delivers antiproliferative drugs, then disappears and is not an impediment for future interventions, surgery or imaging.'

Once fully enrolled, the LIFE-BTK trial will evaluate the Esprit BTK resorbable scaffold in 225 patients at centers around the world. The study is the first of its kind and an evolution of prior studies examining resorbable technology in treating diseased vessels and blocked arteries.

About the LIFE-BTK Trial

The LIFE-BTK trial is the first Investigational Device Exemption trial in the U.S. to evaluate a fully dissolvable device to treat critical limb ischemia in people battling advanced stages of peripheral artery disease (PAD). To date, the trial has sites in Australia, Japan, New Zealand, Singapore and the United States.

The LIFE-BTK trial is a prospective, randomized controlled clinical trial comparing Esprit BTK to Percutaneous Transluminal Angioplasty (PTA). The study objective is to evaluate the safety and efficacy in CLI patients with up to two lesions in separate infrapopliteal vessels, one of three types of vessels found below the knee and the type most commonly affected by CLI.

The trial will be led by principal investigators Brian DeRubertis, M.D. (vascular surgeon, UCLA), Sahil Parikh M.D., (interventional cardiologist, New York-Presbyterian/Columbia University Irving Medical Center, who serves on the medical advisory board for Abbott's vascular division), and Ramon Varcoe MBBS MS FRACS Ph.D., (University New South Wales, Sydney, Australia).

About the Esprit BTK System

The Esprit BTK System consists of a thin strutted scaffold which measures 99 microns made from poly-L-lactide (PLLA), a semi-crystalline bioresorbable polymer engineered to resist vessel recoil and provide a platform for drug delivery. The scaffold is uniformly coated with poly-D, L-lactide (PDLLA) and the cytostatic drug, everolimus. PDLLA is an amorphous bioresorbable polymer coating designed to allow controlled drug release. The controlled release of everolimus, a drug that acts to retard cell proliferation, reduces scar tissue growth in the affected area, which can cause vessel blockage. The Esprit BTK System is an investigational device only in the U.S.

About Critical Limb Ischemia

Critical limb ischemia is a severe form of PAD that is characterized by chronic pain, even at rest, as well as ulcers and gangrene (tissue death) that develop as a result of chronically poor blood flow to the lower limbs. The most common endovascular treatment of below-the-knee arteries is balloon angioplasty, which opens narrowed arteries with a catheter-guided balloon. For some patients, surgical bypass procedures are performed. If left untreated, the disease can eventually lead to amputation and limb loss.

About Abbott

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 107,000 colleagues serve people in more than 160 countries.


Alicia Swanson

Tel: (669) 210-7204

(C) 2020 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
10/30ABBOTT : Wins Prestigious Prix Galien USA Award for First-of-its-Kind MitraClip&..
10/29United to give travelers free COVID-19 tests on select Newark-London flights
10/28Combined Market Cap of Five Largest MedTech Companies Surged by $40bn YoY
10/28JPMorgan appoints General Dynamics CEO as board member
10/28Boston Scientific reports loss as COVID-19 slams demand for medical devices
10/23GLOBAL MARKETS LIVE : Intel, Mattel, NordeaÖ
10/22Quest raises profit forecast as COVID-19 tests demand to jump
10/22ABBOTT LABORATORIES : Reports third-quarter 2020 results, achieves strong double..
10/21ABBOTT LABORATORIES : Raises 2020 Earnings Guidance
10/21ABBOTT LABORATORIES : 3Q Profit, Sales Rise on Covid-19 Testing
More news
Financials (USD)
Sales 2020 33 885 M - -
Net income 2020 4 415 M - -
Net Debt 2020 11 438 M - -
P/E ratio 2020 42,9x
Yield 2020 1,38%
Capitalization 186 B 186 B -
EV / Sales 2020 5,82x
EV / Sales 2021 5,07x
Nbr of Employees 107 000
Free-Float 88,8%
Duration : Period :
Abbott Laboratories Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 117,78 $
Last Close Price 105,11 $
Spread / Highest target 23,7%
Spread / Average Target 12,1%
Spread / Lowest Target -22,0%
EPS Revisions
Robert B. Ford President, CEO, Chief Operating Officer & Director
Miles D. White Executive Chairman
Robert E. Funck Chief Financial Officer & Executive Vice President
Roxanne Schuh Austin Independent Director
Samuel C. Scott Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MEDTRONIC PLC-11.35%136 283